[HTML][HTML] Application of systems biology to identify pharmacological mechanisms of thrombotic microangiopathy evoked by combined activated prothrombin complex …
R Valls, J Wagg, I Paz-Priel, G Man, L Artigas… - Scientific Reports, 2023 - nature.com
Emicizumab is a bispecific monoclonal antibody that substitutes for the function of missing or
deficient factor VIII (FVIII) in people with hemophilia A (PwHA). Long-term safety and efficacy …
deficient factor VIII (FVIII) in people with hemophilia A (PwHA). Long-term safety and efficacy …
Application of systems biology to identify pharmacological mechanisms of thrombotic microangiopathy evoked by combined activated prothrombin complex …
R Valls, J Wagg, I Paz-Priel, G Man, L Artigas… - Scientific …, 2023 - europepmc.org
Emicizumab is a bispecific monoclonal antibody that substitutes for the function of missing or
deficient factor VIII (FVIII) in people with hemophilia A (PwHA). Long-term safety and efficacy …
deficient factor VIII (FVIII) in people with hemophilia A (PwHA). Long-term safety and efficacy …
Application of systems biology to identify pharmacological mechanisms of thrombotic microangiopathy evoked by combined activated prothrombin complex …
R Valls, J Wagg, I Paz-Priel, G Man… - Scientific …, 2023 - ui.adsabs.harvard.edu
Emicizumab is a bispecific monoclonal antibody that substitutes for the function of missing or
deficient factor VIII (FVIII) in people with hemophilia A (PwHA). Long-term safety and efficacy …
deficient factor VIII (FVIII) in people with hemophilia A (PwHA). Long-term safety and efficacy …
[HTML][HTML] Application of systems biology to identify pharmacological mechanisms of thrombotic microangiopathy evoked by combined activated prothrombin complex …
R Valls, J Wagg, I Paz-Priel, G Man, L Artigas… - Scientific …, 2023 - ncbi.nlm.nih.gov
Emicizumab is a bispecific monoclonal antibody that substitutes for the function of missing or
deficient factor VIII (FVIII) in people with hemophilia A (PwHA). Long-term safety and efficacy …
deficient factor VIII (FVIII) in people with hemophilia A (PwHA). Long-term safety and efficacy …
Application of systems biology to identify pharmacological mechanisms of thrombotic microangiopathy evoked by combined activated prothrombin complex …
R Valls, J Wagg, I Paz-Priel, G Man… - Scientific …, 2023 - search.ebscohost.com
Emicizumab is a bispecific monoclonal antibody that substitutes for the function of missing or
deficient factor VIII (FVIII) in people with hemophilia A (PwHA). Long-term safety and efficacy …
deficient factor VIII (FVIII) in people with hemophilia A (PwHA). Long-term safety and efficacy …
Application of systems biology to identify pharmacological mechanisms of thrombotic microangiopathy evoked by combined activated prothrombin complex …
R Valls, J Wagg, I Paz-Priel, G Man… - Scientific …, 2023 - pubmed.ncbi.nlm.nih.gov
Emicizumab is a bispecific monoclonal antibody that substitutes for the function of missing or
deficient factor VIII (FVIII) in people with hemophilia A (PwHA). Long-term safety and efficacy …
deficient factor VIII (FVIII) in people with hemophilia A (PwHA). Long-term safety and efficacy …
Application of systems biology to identify pharmacological mechanisms of thrombotic microangiopathy evoked by combined activated prothrombin complex …
R Valls, J Wagg, I Paz-Priel, G Man, L Artigas… - Scientific …, 2023 - europepmc.org
Emicizumab is a bispecific monoclonal antibody that substitutes for the function of missing or
deficient factor VIII (FVIII) in people with hemophilia A (PwHA). Long-term safety and efficacy …
deficient factor VIII (FVIII) in people with hemophilia A (PwHA). Long-term safety and efficacy …